Searched for
SUDARSHAN JAIN
Strengthening the India-US medicines partnership important: IPAThe Indian Pharmaceutical Alliance welcomed an interim trade agreement between India and the US, emphasizing that medicine security is cruc...- Budget 2026: Pharma, med-tech companies seek PLI extension to cover APIsThe industry expects the government to address these issues in the Union budget announcement this year. Sudarshan Jain, secretary general o...
- IPA names Zydus Lifesciences MD Sharvil Patel as PresidentSharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice p...
- Healthcare set to be more affordable as new GST rate kicks in from Sep 22: Pharma industryFrom September 22, medicines and medical devices in India will become cheaper under new GST rates, making healthcare more affordable, say i...
- Crucial drugs to be more affordable after GST cutThe government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart cond...
- Sudarshan Chakra Mission: Inspired by Lord Krishna, India’s Iron Dome-like system 'will not only defend but also punish the enemy'Sudarshan Chakra Mission: Prime Minister Modi has announced Mission Sudarshan Chakra, a comprehensive national security initiative to safeg...
- COVID-19 vaccines well-documented, rigorously tested as per regulatory processes: IPAThe Indian Pharmaceutical Alliance (IPA) refuted claims linking COVID-19 vaccines to heart attack deaths, emphasizing their rigorous testin...
- Indian Pharmaceutical Alliance calls for zero import duty on US drugs to boost local industryThe Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero. Currently, India imp...
- Linking spurious drugs with legitimate manufacturers has severe reputational, financial impact: IPAThe Indian Pharmaceutical Alliance (IPA) has called for a clear distinction between spurious and sub-standard drugs following a CDSCO repor...
- Top individual investors made more money in June quarterThe Jhunjhunwala family's wealth in listed firms, which surpassed ₹50,000 crore for the first time in the March quarter, declined by nearly...
- Budget 2024: Pharma industry seeks incentives for R&D, conducive policiesIn the upcoming union budget 2024, the Indian pharmaceutical industry is seeking fiscal incentives to promote research and development (R&D...
- Drugmakers' body IPA says it's examining the controversy around Dolo medicineMicro Labs has rejected the allegations, terming them as "baseless". Sudarshan Jain, secretary general of IPA, told ET its member companies...
- Exclude cheap drugs from price control: IPASudarshan Jain, secretary general of IPA, in an interview to ET said "We are not against price controls; what we are saying is that the gov...
- Panel for removing penal provisions from proposed Drugs Act for lapsesThe existing Drugs and Cosmetics Act, 1940 is prosecutable. Any drug/cosmetic deemed to be adulterated or spurious is punishable with impri...
- Realisation there in pharma industry to become self reliant in API production: IPA"Reliance on China for APIs is there...We had the technology of making all kinds of APIs but over a period of time we lost that advantage. ...
- A growth formula for generics, biosimilarsUnder the scheme, financial incentives will be given to eligible manufacturers of complex generics and biopharmaceuticals on their sales ov...
- Modi's 'self-reliance' call need of the hour: Pharma industryDuring these unprecedented times, the pharmaceutical industry has worked with the government in an integrated manner and continued to opera...
- Shipment of hydroxychloroquine to US likely to start next week: IPA"The shipments of hydroxychloroquine to the US are likely to start next week. Indian pharma companies are committed to meet both, domestic ...
- Prolongation of coronavirus outbreak in China could hit Indian pharma sectorChina accounted for 67.56 per cent of total imports of bulk drugs and drug intermediates in 2018-19 at USD 2,405.42 million. "The situation...
- Indian pharma cos need to focus on innovation & complex generics: Sudarshan Jain"Open up pharma market, it will be win-win for Indian companies as well as China."
Load More
